Canadian application, no grantCanada
Methods for treating rheumatoid arthritis using il-17 antagonists
CA 2425506 A1 · Owner: Kirin-Amgen, Inc. · Inventors: Mohler, Kendall M.
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method of treating a mammal afflicted with rheumatoid arthritis comprising administering a soluble form of IL-17 receptor an IL-17 receptor antibody or , a polypeptide fragment having at least 70 % identity to the IL-17.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 18, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 18, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 18, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledOctober 18, 2001
GrantedNo grant recorded
Term endedOctober 18, 2021
Patent numberCA 2425506 A1
Classification (IPC)C07K14/54 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.